Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1390392 | 0.95 | HPGD (0.39) | BRD4P2RX7 | |
| SCHEMBL368971 | 0.92 | F9 (0.36) | BRD4IDH1DGAT2RORC | |
| SCHEMBL1390395 | 0.92 | BRD4 (0.41) | BRD4P2RX7IDH1RORC | |
| SCHEMBL1390183 | 0.92 | HPGD (0.37) | BRD4P2RX7 | |
| SCHEMBL1390181 | 0.92 | HPGD (0.37) | BRD4P2RX7 | |
| SCHEMBL1390393 | 0.92 | BRD4 (0.41) | BRD4P2RX7IDH1RORC | |
| SCHEMBL369884 | 0.91 | BRD4 (0.38) | BRD4P2RX7IDH1MAPK1DGAT2 | |
| SCHEMBL1389815 | 0.91 | BRD4 (0.38) | BRD4P2RX7IDH1MAPK1DGAT2 | |
| SCHEMBL1389811 | 0.91 | BRD4 (0.38) | BRD4P2RX7IDH1MAPK1DGAT2 | |
| SCHEMBL1390352 | 0.90 | ACHE (0.36) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | BRD4 3540/4885P2RX7 248/4885IDH1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.